An approaching EU GMP inspection can make even a capable manufacturing team feel uneasy. We understand that pressure. Production must continue, records need attention, and every unresolved deviation suddenly feels urgent. As an EU GMP compliance services provider in India, we help you turn that uncertainty into practical work. CPC India’s approach starts with a simple question: can your everyday operations support what your procedures promise?
Founded in 2002, CPC India offers quality, regulatory and project consultancy to pharmaceutical and chemical businesses. We bring together practical guidance and a clear understanding of manufacturing pressures. And we believe preparation becomes more manageable when we discuss weaknesses openly, without turning every conversation into a hunt for mistakes.
The hardest part is often consistency. We need the approved procedure, the actual activity and the supporting record to tell the same story across every shift.
For Indian manufacturers preparing for European supply, we focus on several recurring challenges:
We shouldn’t treat this as a ranking of deficiencies across Indian facilities. Your priorities depend on your products, processes and existing controls.
Before recommending changes, we establish your manufacturing scope. Finished medicinal products generally fall under EU GMP Part I, while active substances fall under Part II. We then identify the relevant annexes and product requirements.
CPC India helps you connect that scope with your facility and intended supply arrangements. An ISO certificate or domestic manufacturing licence doesn’t, by itself, demonstrate EU GMP compliance. We also separate inspection readiness from marketing authorisation and import requirements, because completing one step doesn’t automatically complete the rest.
A signed report can look reassuring. But we need to understand how the result was generated, reviewed and retained.
Consider a hypothetical laboratory in Hyderabad: two analysts share one instrument login during a busy evening shift. The results might be accurate, yet establishing who performed each action becomes difficult. That’s a control weakness worth addressing before an inspection.
We look for attributable, legible, contemporaneous, original and accurate records, alongside completeness, consistency, endurance and availability. Paper records deserve the same attention as electronic systems.
CPC India supports a practical review of access controls, audit trails, original data and record handling. We ask whether your team can retrieve the full history, including failed runs and justified corrections. A clean final printout cannot explain everything.
We understand the temptation to close an overdue investigation quickly. Still, “operator error” rarely gives us enough information.
Was the instruction unclear? Did equipment behave unexpectedly? Was the workload unrealistic? We need evidence before choosing a root cause, and we need to assess any impact on other batches or products.
When we discuss what the best EU GMP compliance company in India should offer, our answer starts with useful investigation support. We help you connect the event, the evidence, the corrective action and the effectiveness check. A polished report has limited value if the same failure returns next month.
CPC India encourages clear ownership and realistic deadlines for corrective and preventive actions, or CAPA. We also look beyond closure dates. If repeated deviations continue after retraining, we need to reconsider the diagnosis, not simply schedule another training session.
Qualification and validation can become paperwork exercises when production deadlines take over. We see the underlying question differently: can you demonstrate that the process remains controlled during routine use?
An initial successful study matters. So does what happens after a change in batch size, equipment, cleaning conditions or raw material characteristics.
CPC India helps you connect validation evidence with actual operating conditions. We don’t assume every change requires complete revalidation. We assess the potential impact, document the reasoning and identify the work needed to maintain control.
For sterile manufacturing, we need a contamination control strategy that connects facility design, personnel practices, utilities, materials and process controls. Annex 1 expects these measures to work together.
Testing alone cannot assure sterility. That can feel uncomfortable when laboratory results have always been the main source of reassurance, but prevention must begin much earlier.
As an EU GMP compliance services provider in India, we help you examine how contamination could enter or move through your process. We consider personnel and material flows, cleaning practices, maintenance activities and interventions. For non-sterile operations, we assess applicable contamination and cross-contamination controls without assuming every sterile requirement applies.
Sometimes, the useful starting point is simply walking the route of a material container. Where does it wait? What touches it? Which record confirms its status?
Approving a supplier is a beginning. We still need confidence in material quality, change communication and the reliability of supporting information.
We review supplier qualification according to risk and clarify responsibilities for outsourced testing or manufacturing. A quality agreement should explain how deviations, changes and relevant information reach your quality team.
We also check that your European supply arrangements identify the applicable importer and Qualified Person responsibilities. Consultancy support can strengthen readiness, but we cannot replace the responsibilities assigned to manufacturers, importers or competent authorities.
A signed attendance sheet proves attendance. It doesn’t show whether your operator can recognise an unexpected condition or explain when to stop work.
We favour training built around actual tasks. Ask your team to demonstrate a record correction, explain an alarm response or locate the current procedure. Small exercises can reveal confusion before a batch is affected.
Through ISO gap analysis in India, we can help you examine relevant management-system weaknesses, including document control and training arrangements. We keep that assessment distinct from an EU GMP gap assessment, which must address pharmaceutical requirements directly.
CPC India helps you prioritise findings by risk, assign ownership and establish evidence of completion. We want your team to understand the reason behind a control, rather than memorise a sentence for inspection day.
Start with an honest baseline. We recommend reviewing a recent batch from incoming materials through testing and release, then following any gaps into the supporting systems.
Our ISO gap analysis in India can support broader quality-system improvement where relevant. Alongside a dedicated GMP assessment, it helps us distinguish organisational weaknesses from specific pharmaceutical compliance gaps.
There’s no responsible fixed promise for inspection readiness. Your timeline depends on the starting condition, available resources and necessary facility or system changes.
CPC India works towards the standard you should expect from the best EU GMP compliance company in India: clear advice, practical priorities and support grounded in evidence. We can start with the issue causing the most concern and build a workable plan from there.